145934-92-5

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[2,3-b]pyridine,5-fluoro-2-methyl-(9CI) is utilized as a building block or intermediate in the synthesis of other organic compounds. Its specific properties and potential applications are under research and development for its use in drug discovery and development, making it a valuable component in the creation of novel pharmaceuticals.
In the pharmaceutical industry, the compound's unique structure and functional groups may offer advantages in the design of new drugs, potentially leading to the development of innovative therapeutic agents. 1H-Pyrrolo[2,3-b]pyridine,5-fluoro-2-methyl-(9CI)'s heterocyclic nature and the presence of fluorine and methyl groups may contribute to its reactivity, stability, and interaction with biological targets, which are essential factors in drug design and optimization.

InChI:InChI=1/C8H7FN2/c1-5-2-6-3-7(9)4-10-8(6)11-5/h2-4H,1H3,(H,10,11)

Upstream product

• 869557-43-7 3-bromo-5-fluoropyridin-2-amine 
• 1312755-46-6 5-fluoro-3-prop-1-ynyl-pyridin-2-ylamine 
• 823218-51-5 5-fluoro-3-iodo-pyridin-2-amine 
• 21717-96-4 2-amino-5-fluoropyridine 

Relevant academic research and scientific papers

Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza

JNJ-63623872 (2) is a first-in-class, orally bioavailable compound that offers significant potential for the treatment of pandemic and seasonal influenza. Early lead optimization efforts in our 7-azaindole series focused on 1,3-diaminocyclohexyl amide and urea substitutions on the pyrimidine-7-azaindole motif. In this work, we explored two strategies to eliminate observed aldehyde oxidase (AO)-mediated metabolism at the 2-position of these 7-azaindole analogues. Substitution at the 2-position of the azaindole ring generated somewhat less potent analogues, but reduced AO-mediated metabolism. Incorporation of a ring nitrogen generated 7-azaindazole analogues that were equipotent to the parent 2-H-7-azaindole, but surprisingly, did not appear to improve AO-mediated metabolism. Overall, we identified multiple 2-substituted 7-azaindole analogues with enhanced AO stability and we present data for one such compound (12) that demonstrate a favorable oral pharmacokinetic profile in rodents. These analogues have the potential to be further developed as anti-influenza agents for the treatment of influenza.

Asymmetric Hydrogenation of Azaindoles: Chemo- and Enantioselective Reduction of Fused Aromatic Ring Systems Consisting of Two Heteroarenes

High enantioselectivity was achieved for the hydrogenation of azaindoles by using the chiral catalyst, which was prepared from [Ru(η3-methallyl)2(cod)] and a trans-chelating bis(phosphine) ligand (PhTRAP). The dearomative reaction exclusively occurred on the five-membered ring, thus giving the corresponding azaindolines with up to 97:3 enantiomer ratio.

1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER

The invention relates to 1, 7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk 1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

ACTIVE COMPOUNDS

Therapeutically active compounds of the formula: wherein the variables are defined in the specification are provided